Citadel Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-571,529
| Closed | -$58.3M | – | 15470 |
|
|
2023
Q2 | $58.3M | Buy |
571,529
+539,322
| +1,675% | +$51M | 0.01% | 933 |
|
|
2023
Q1 | $2.93M | Sell |
32,207
-42,429
| -57% | -$2.49M | ﹤0.01% | 4670 |
|
|
2022
Q4 | $2.84M | Sell |
74,636
-87,179
| -54% | -$3M | ﹤0.01% | 4844 |
|
|
2022
Q3 | $4.07M | Sell |
161,815
-66,688
| -29% | -$1.85M | ﹤0.01% | 4225 |
|
|
2022
Q2 | $6.94M | Buy |
228,503
+99,660
| +77% | +$2.97M | ﹤0.01% | 3216 |
|
|
2022
Q1 | $4.22M | Buy |
128,843
+68,422
| +113% | +$2.03M | ﹤0.01% | 4514 |
|
|
2021
Q4 | $1.59M | Buy |
60,421
+54,228
| +876% | +$4.2M | ﹤0.01% | 6745 |
|
|
2021
Q3 | $623K | Buy |
+6,193
| New | +$726K | ﹤0.01% | 9339 |
|
|
2021
Q2 | – | Sell |
-21,229
| Closed | -$2.4M | – | 14683 |
|
|
2021
Q1 | $2.12M | Sell |
21,229
-2,274
| -10% | -$265K | ﹤0.01% | 6259 |
|
|
2020
Q4 | $2.91M | Sell |
23,503
-10,369
| -31% | -$1.36M | ﹤0.01% | 4635 |
|
|
2020
Q3 | $3.3M | Sell |
33,872
-19,908
| -37% | -$2.49M | ﹤0.01% | 3828 |
|
|
2020
Q2 | $8.39M | Sell |
53,780
-22,141
| -29% | -$3.37M | ﹤0.01% | 2433 |
|
|
2020
Q1 | $11M | Buy |
75,921
+41,951
| +123% | +$8.1M | ﹤0.01% | 1757 |
|
|
2019
Q4 | $6.95M | Buy |
33,970
+20,598
| +154% | +$3.76M | ﹤0.01% | 2652 |
|
|
2019
Q3 | $1.07M | Buy |
13,372
+5,503
| +70% | +$467K | ﹤0.01% | 5474 |
|
|
2019
Q2 | $742K | Sell |
7,869
-6,828
| -46% | -$590K | ﹤0.01% | 6198 |
|
|
2019
Q1 | $1.26M | Buy |
14,697
+9,267
| +171% | +$769K | ﹤0.01% | 5197 |
|
|
2018
Q4 | $305K | Sell |
5,430
-34,732
| -86% | -$2.12M | ﹤0.01% | 7243 |
|
|
2018
Q3 | $3.28M | Buy |
40,162
+31,880
| +385% | +$2.25M | ﹤0.01% | 3588 |
|
|
2018
Q2 | $290K | Sell |
8,282
-15,970
| -66% | -$486K | ﹤0.01% | 7265 |
|
|
2018
Q1 | $497K | Buy |
+24,252
| New | +$624K | ﹤0.01% | 5899 |
|
|
2017
Q4 | – | Sell |
-8,232
| Closed | -$256K | – | 8574 |
|
|
2017
Q3 | $256K | Buy |
+8,232
| New | +$248K | ﹤0.01% | 6313 |
|
Other funds holding RETA
Citadel Advisors's RETA Position: Q3 2023 in Review
Citadel Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 571,529 shares — an estimated $58.3M sold.
Citadel Advisors first reported a position in RETA in Q3 2017 and held it in 22 quarters. The position peaked at $58.3M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Citadel Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Citadel Advisors sold 571,529 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $58.3M.
- Citadel Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 22 quarters.
- Citadel Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $58.3M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.